Using intravenous Lidocaine to manage pain after liver surgery
Intravenous Lidocaine for Postoperative Recovery in Liver Surgery, a Randomized Double Blinded Placebo-controlled Study
This study is testing if giving Lidocaine through an IV during liver surgery can help reduce pain and the need for opioid painkillers afterwards for patients having minor liver surgery due to cancer.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lund University Hospital Academic / other |
| Locations | 1 site (Lund, Skåne) |
| Trial ID | NCT05153785 on ClinicalTrials.gov |
What this trial studies
This randomized double-blinded placebo-controlled study aims to evaluate the effectiveness of intravenous Lidocaine in reducing postoperative pain and opioid consumption in patients undergoing minor hepatectomy for liver cancer or metastases. Participants will be randomly assigned to receive either Lidocaine or a placebo during their surgery, followed by routine pain management with Patient Controlled Analgesia (PCA) using Oxycodone. Pain intensity will be assessed at various intervals post-surgery to determine the impact of Lidocaine on pain management. The study is conducted at Lund University Hospital in Sweden.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for minor hepatectomy.
Not a fit: Patients with severe liver conditions, ongoing opioid use, or certain cardiac and neurological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce postoperative pain and opioid use in liver surgery patients.
How similar studies have performed: Previous studies have shown promising results with intravenous Lidocaine for pain management, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 yy * Patient planned for minor hepatectomy * Signed informed consent Exclusion Criteria: * Pregnancy * Cirrosis * ASA\>3 * Elevated liver enzymes * AV-block \>1, without pacemaker * WHO class \>2 * Allergy against Lidocain or other amid-type local anasthesia * Heart failure * Epilepsy * Treatment with class III anti-arythimic medication * Preoperative ongoing opioid usage * Use of : Erythromycin, clarithromycin, Fluvoxamine, Cimetidine, ciprofloxacin, antivirala-HIV-läkemedel or imidazol the week before surgery.
Where this trial is running
Lund, Skåne
- Skåne University Hospital of Lund — Lund, Skåne, Sweden (Recruiting)
Study contacts
- Study coordinator: Emil Östrand, MD
- Email: emil.ostrand@skane.se
- Phone: +46-(0)46-171000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.